Hansa Biopharma Valuation
| HNSBF Stock | USD 2.93 0.00 0.00% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Hansa Biopharma AB retains a regular Real Value of $3.02 per share. The prevalent price of the firm is $2.93. Our model calculates the value of Hansa Biopharma AB from evaluating the firm fundamentals such as Shares Owned By Insiders of 7.37 %, return on asset of -0.27, and Return On Equity of -0.89 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage locking in undervalued assets and disposing overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Fairly Valued
Today
Please note that Hansa Biopharma's price fluctuation is unstable at this time. Calculation of the real value of Hansa Biopharma AB is based on 3 months time horizon. Increasing Hansa Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Hansa Biopharma AB is useful when determining the fair value of the Hansa pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Hansa Biopharma. Since Hansa Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hansa Pink Sheet. However, Hansa Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.93 | Real 3.02 | Hype 2.93 | Naive 2.89 |
The real value of Hansa Pink Sheet, also known as its intrinsic value, is the underlying worth of Hansa Biopharma AB Company, which is reflected in its stock price. It is based on Hansa Biopharma's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Hansa Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Hansa Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Hansa Biopharma AB helps investors to forecast how Hansa pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hansa Biopharma more accurately as focusing exclusively on Hansa Biopharma's fundamentals will not take into account other important factors: Hansa Biopharma Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Hansa Biopharma's current stock value. Our valuation model uses many indicators to compare Hansa Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hansa Biopharma competition to find correlations between indicators driving Hansa Biopharma's intrinsic value. More Info.Hansa Biopharma AB is one of the top stocks in price to earning category among related companies. It is rated # 2 in price to book category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hansa Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hansa Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hansa Biopharma's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Hansa Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Hansa Biopharma and how it compares across the competition.
About Hansa Biopharma Valuation
The pink sheet valuation mechanism determines the current worth of Hansa Biopharma AB on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Hansa Biopharma AB. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Hansa Biopharma AB based exclusively on its fundamental and basic technical indicators. By analyzing Hansa Biopharma's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Hansa Biopharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Hansa Biopharma. We calculate exposure to Hansa Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Hansa Biopharma's related companies.Hansa Biopharma AB , a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G -mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. Hansa Biopharma AB was incorporated in 2007 and is headquartered in Lund, Sweden. Hansa Medical is traded on OTC Exchange in the United States.
8 Steps to conduct Hansa Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Hansa Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Hansa Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Hansa Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Hansa Biopharma's revenue streams: Identify Hansa Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Hansa Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Hansa Biopharma's growth potential: Evaluate Hansa Biopharma's management, business model, and growth potential.
- Determine Hansa Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Hansa Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Hansa Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Hansa Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 44.5 M | |
| Retained Earnings | -1.9 B |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Hansa Pink Sheet analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |